Trial Profile
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2-AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs GSK 208141 (Primary) ; AS04A; Hepatitis A vaccine inactivated
- Indications Hepatitis A
- Focus Adverse reactions; Registrational
- Sponsors GlaxoSmithKline; GSK
- 09 Oct 2008 Actual start date changed from April 2004 to November 2003, as reported by ClinicalTrials.gov. Actual patient number reported as 5960.
- 28 Jan 2008 Status changed from in progress to completed; according to clinicaltrials.gov.
- 02 Nov 2005 New trial record.